Stockreport
Results from Phase I Study of CB-839 in Combination with Everolimus or Cabozantinib in Patients with Renal Cell Carcinoma to be Presented at the 2018 American Society of Clinical Oncology ...
Calithera Biosciences, Inc. (CALA)
More Company Research
Source: GlobeNewswire
Last calithera biosciences, inc. earnings: 3/11 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations: calithera.com
PDF
-Overall response rate of 40% and 100% disease control rate in advanced clear cell renal cell carcinoma patients treated with CB-839 plus Cabozantinib -Randomized place
[Read more]
IMPACT SNAPSHOT
EVENT TIME:
{{FirstSection.LastPriceAtNewsEventTime2}}
CALA
Last Price
{{SecondSection.LastPrice}}
Price Change
{{SecondSection.PriceChange}} {{SecondSection.PriceChangeTriangle_AMP}}
Price Change %
{{SecondSection.PriceChangePercent}} {{SecondSection.PriceChangeTriangle_AMP}}
Volume Shares
{{SecondSection.Volume}}
Max Up
{{SecondSection.MaxUp}}
Max Down
{{SecondSection.MaxDown}}
Volume Ratio
{{SecondSection.VolumeImpactStr_AMP}}%
{{SecondSection.PriceChangePercent}}
Don't Miss Out On The Next BIG Stock Move
{{GreenBoxData.Blurb}}
Performance comparison
Updated
{{SecondSection.VwapEventTime}}
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST PRICE AT
NEWS EVENT {{SecondSection.LastPriceAtNewsEvent}}
|
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
{{FirstSection.LastPrice}}
|
LAST PRICE |
{{SecondSection.LastPrice}}
|
{{FirstSection.VWapStr_AMP}}
{{FirstSection.VwapEventTime}}
|
VWAP |
{{SecondSection.VWapStr_AMP}}
{{SecondSection.VwapEventTime}}
|
{{FirstSection.MaxUp}}
High: {{FirstSection.EodHigh}}
|
MAX UP |
{{SecondSection.MaxUp}}
High: {{SecondSection.EodHigh}}
|
{{FirstSection.MaxDown}}
Low: {{FirstSection.EodLow}}
|
MAX DOWN |
{{SecondSection.MaxDown}}
Low: {{SecondSection.EodLow}}
|
{{FirstSection.TodaysRangeStr_AMP}}
{{FirstSection.RangEvg}}
|
POST NEWS RANGE |
{{SecondSection.TodaysRangeStr_AMP}}
{{SecondSection.RangEvg}}
|
{{FirstSection.PriceChange}}
{{FirstSection.PriceChangeTriangle_AMP}}
|
PRICE CHANGE |
{{SecondSection.PriceChange}}
{{SecondSection.PriceChangeTriangle_AMP}}
|
{{FirstSection.PriceChangePercent}}
|
PRICE CHANGE PERCENTAGE |
{{SecondSection.PriceChangePercent}}
|
{{FirstSection.Spx500}}
|
S&P 500 (SPX) |
{{SecondSection.Spx500}}
|
{{FirstSection.VolumeImpactStr_AMP}}
|
VOLUME RATIO |
{{SecondSection.VolumeImpactStr_AMP}}
|
{{FirstSection.Volume}}
|
VOLUME (SHARES) |
{{SecondSection.Volume}}
|
{{FirstSection.TicksString}}
|
TICKS |
{{SecondSection.TicksString}}
|
{{FirstSection.AvgTransactionSizeStr_AMP}}
|
AVG SHARES PER TRADE |
{{SecondSection.AvgTransactionSizeStr_AMP}}
|
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY